Insider Selling: Dermira Inc (DERM) Director Sells 600 Shares of Stock
Dermira Inc (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $25.49, for a total transaction of $15,294.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Dermira Inc (NASDAQ:DERM) remained flat at $$24.21 during midday trading on Tuesday. The company’s stock had a trading volume of 303,751 shares, compared to its average volume of 425,743. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a one year low of $21.35 and a one year high of $38.75.
A number of research analysts recently issued reports on the stock. Leerink Swann reiterated an “outperform” rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. BidaskClub upgraded shares of Dermira from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. Mizuho reiterated a “buy” rating and issued a $43.00 target price (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $43.33.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.